For , Pfizer may remain a "dead money" asset due to the lack of immediate revenue drivers. However, for long-term value and income investors , the stock offers a rare combination of a high, sustainable yield and the potential for a significant "re-rating" once the market gains confidence in its post-2028 growth engine.
: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings. buy pfizer stock
: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 . For , Pfizer may remain a "dead money"
The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars: This "soft" outlook has led many major brokerages,
AI responses may include mistakes. For financial advice, consult a professional. Learn more
: Pfizer remains a premier income stock, offering a 6.42% dividend yield . Management has reaffirmed its commitment to the dividend, declaring a $0.43 per share payout for the second quarter of 2026. While the payout ratio is elevated, management's cost-realignment program—targeting $7.2 billion in cumulative savings by 2027 —is intended to protect these cash returns.
As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500.